0000950170-24-029536.txt : 20240311
0000950170-24-029536.hdr.sgml : 20240311
20240311200232
ACCESSION NUMBER: 0000950170-24-029536
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240308
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wigzell Hans Lennart Rudolf
CENTRAL INDEX KEY: 0001492766
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 24739842
MAIL ADDRESS:
STREET 1: OSKAR BAECKSTROMSV.11
CITY: HAGERSTEN
STATE: V7
ZIP: 12935
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
ownership.xml
4
X0508
4
2024-03-08
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001492766
Wigzell Hans Lennart Rudolf
215 FIRST STREET
SUITE 415
CAMBRIDGE
MA
02142
true
false
false
false
false
Common Stock
2024-03-08
4
M
false
15000
13.90
A
37840
D
Common Stock
2024-03-08
4
S
false
3155
123.85
D
34685
D
Common Stock
2024-03-08
4
S
false
11745
123.10
D
22940
D
Common Stock
2024-03-08
4
S
false
100
122.39
D
22840
D
Stock Option (right to buy)
13.90
2024-03-08
4
M
false
15000
0
D
2016-02-27
2035-02-27
Common Stock
15000
0
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.6 to $124.6, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $122.65 to $123.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
/s/ Ryan Brown, as Attorney-in-Fact for Hans Wigzell
2024-03-11